Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial.

TitleEfficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial.
Publication TypeJournal Article
Year of Publication2014
AuthorsLennox JL, Landovitz RJ, Ribaudo HJ, Ofotokun I, Na LH, Godfrey C, Kuritzkes DR, Sagar M, Brown TT, Cohn SE, McComsey GA, Aweeka F, Fichtenbaum CJ, Presti RM, Koletar SL, Haas DW, Patterson KB, Benson CA, Baugh BP, Leavitt RY, Rooney JF, Seekins D, Currier JS
Corporate AuthorsACTG A5257 Team
JournalAnn Intern Med
Volume161
Issue7
Pagination461-71
Date Published2014 Oct 7
ISSN1539-3704
KeywordsAdenine, Adult, Atazanavir Sulfate, Darunavir, Deoxycytidine, Drug Combinations, Drug Therapy, Combination, Emtricitabine, Female, HIV Infections, HIV Protease Inhibitors, HIV-1, Humans, Male, Oligopeptides, Organophosphonates, Pyridines, Reverse Transcriptase Inhibitors, RNA, Viral, Sulfonamides, Tenofovir, Therapeutic Equivalency, Viral Load
Abstract

BACKGROUND: Nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy is not suitable for all treatment-naive HIV-infected persons.

OBJECTIVE: To evaluate 3 nonnucleoside reverse transcriptase inhibitor-sparing initial antiretroviral regimens to show equivalence for virologic efficacy and tolerability.

DESIGN: A phase 3, open-label study randomized in a 1:1:1 ratio with follow-up for at least 96 weeks. (ClinicalTrials.gov: NCT00811954).

SETTING: 57 sites in the United States and Puerto Rico.

PATIENTS: Treatment-naive persons aged 18 years or older with HIV-1 RNA levels greater than 1000 copies/mL without resistance to nucleoside reverse transcriptase inhibitors or protease inhibitors.

INTERVENTION: Atazanavir, 300 mg/d, with ritonavir, 100 mg/d; raltegravir, 400 mg twice daily; or darunavir, 800 mg/d, with ritonavir, 100 mg/d, plus combination emtricitabine, 200 mg/d, and tenofovir disoproxil fumarate, 300 mg/d.

MEASUREMENTS: Virologic failure, defined as a confirmed HIV-1 RNA level greater than 1000 copies/mL at or after 16 weeks and before 24 weeks or greater than 200 copies/mL at or after 24 weeks, and tolerability failure, defined as discontinuation of atazanavir, raltegravir, or darunavir for toxicity. A secondary end point was a combination of virologic efficacy and tolerability.

RESULTS: Among 1809 participants, all pairwise comparisons of incidence of virologic failure over 96 weeks showed equivalence within a margin of equivalence defined as -10% to 10%. Raltegravir and ritonavir-boosted darunavir were equivalent for tolerability, whereas ritonavir-boosted atazanavir resulted in a 12.7% and 9.2% higher incidence of tolerability discontinuation than raltegravir and ritonavir-boosted darunavir, respectively, primarily because of hyperbilirubinemia. For combined virologic efficacy and tolerability, ritonavir-boosted darunavir was superior to ritonavir-boosted atazanavir, and raltegravir was superior to both protease inhibitors. Antiretroviral resistance at the time of virologic failure was rare but more frequent with raltegravir.

LIMITATION: The trial was open-label, and ritonavir was not provided.

CONCLUSION: Over 2 years, all 3 regimens attained high and equivalent rates of virologic control. Tolerability of regimens containing raltegravir or ritonavir-boosted darunavir was superior to that of the ritonavir-boosted atazanavir regimen.

PRIMARY FUNDING SOURCE: National Institute of Allergy and Infectious Diseases.

DOI10.7326/M14-1084
Alternate JournalAnn. Intern. Med.
PubMed ID25285539
PubMed Central IDPMC4412467
Grant List1U01AI069494 / AI / NIAID NIH HHS / United States
1UL1TR001111 / TR / NCATS NIH HHS / United States
2 UM1 AI068636-08 / AI / NIAID NIH HHS / United States
2 UM1 AI069503-08 / AI / NIAID NIH HHS / United States
2UM1 AI069418-08 / AI / NIAID NIH HHS / United States
2UM1 AI069465 / AI / NIAID NIH HHS / United States
2UM1 AI069511-08 / AI / NIAID NIH HHS / United States
2UM1-AI069470-08 / AI / NIAID NIH HHS / United States
2UM1A1069412-08 / / PHS HHS / United States
2UM1AI069412-08 / AI / NIAID NIH HHS / United States
2UM1AI069415-09 / AI / NIAID NIH HHS / United States
2UM1AI069432 / AI / NIAID NIH HHS / United States
2UM1AI069439-08 / AI / NIAID NIH HHS / United States
2UM1AI069452-08 / AI / NIAID NIH HHS / United States
2UM1AI069503-08 / AI / NIAID NIH HHS / United States
5-P30-AI-045008-15 / AI / NIAID NIH HHS / United States
5U01 AI069471 / AI / NIAID NIH HHS / United States
5UL1 RR024156; / RR / NCRR NIH HHS / United States
5UM1 AI069484-07 / AI / NIAID NIH HHS / United States
A1069423-08 / / PHS HHS / United States
A1069424 / / PHS HHS / United States
AI 69501 / AI / NIAID NIH HHS / United States
AI-069471 / AI / NIAID NIH HHS / United States
AI069424 / AI / NIAID NIH HHS / United States
AI069432 / AI / NIAID NIH HHS / United States
AI069439 / AI / NIAID NIH HHS / United States
AI069471 / AI / NIAID NIH HHS / United States
AI069477 / AI / NIAID NIH HHS / United States
AI069501 / AI / NIAID NIH HHS / United States
AI069556 / AI / NIAID NIH HHS / United States
AI69432 / AI / NIAID NIH HHS / United States
P30 AI027763 / AI / NIAID NIH HHS / United States
P30 AI050409 / AI / NIAID NIH HHS / United States
P30 AI060354 / AI / NIAID NIH HHS / United States
P30 AI50410 / AI / NIAID NIH HHS / United States
U01 AI068636 / AI / NIAID NIH HHS / United States
U01 AI069418 / AI / NIAID NIH HHS / United States
U01 TR000445 / TR / NCATS NIH HHS / United States
U01AI069447 / AI / NIAID NIH HHS / United States
UL1 TR000004 / TR / NCATS NIH HHS / United States
UL1 TR000170 / TR / NCATS NIH HHS / United States
UL1 TR000170 / TR / NCATS NIH HHS / United States
UL1 TR000439 / TR / NCATS NIH HHS / United States
UL1 TR000454 / TR / NCATS NIH HHS / United States
UL1 TR001082 / TR / NCATS NIH HHS / United States
UL1 TR001082 / TR / NCATS NIH HHS / United States
UL1 TR024160 / TR / NCATS NIH HHS / United States
UL1TR000058 / TR / NCATS NIH HHS / United States
UL1TR000124 / TR / NCATS NIH HHS / United States
UL1TR000439 / TR / NCATS NIH HHS / United States
UL1TR000457 / TR / NCATS NIH HHS / United States
UL1TR001079 / TR / NCATS NIH HHS / United States
UM 1 A1069503 / / PHS HHS / United States
UM AI069481 / AI / NIAID NIH HHS / United States
UM1 AI068634 / AI / NIAID NIH HHS / United States
UM1 AI068636 / AI / NIAID NIH HHS / United States
UM1 AI069418 / AI / NIAID NIH HHS / United States
UM1 AI069423-08 / AI / NIAID NIH HHS / United States
UM1 AI069439 / AI / NIAID NIH HHS / United States
UM1 AI069472 / AI / NIAID NIH HHS / United States
UM1 AI069494 / AI / NIAID NIH HHS / United States
UM1 AI069494. / AI / NIAID NIH HHS / United States
UM1 AI069496 / AI / NIAID NIH HHS / United States
UM1 AI069503 / AI / NIAID NIH HHS / United States
UM1 AI069532 / AI / NIAID NIH HHS / United States
UM1 AI106701 / AI / NIAID NIH HHS / United States
UM1-AI069534-08 / AI / NIAID NIH HHS / United States
UM1AI068636 / AI / NIAID NIH HHS / United States
UM1AI069419 / AI / NIAID NIH HHS / United States
UM1AI069439 / AI / NIAID NIH HHS / United States
UM1AI069472 / AI / NIAID NIH HHS / United States
UM1AI069494 / AI / NIAID NIH HHS / United States
UM1AI68634 / AI / NIAID NIH HHS / United States